Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Jane Street Group LLC

Jane Street Group LLC decreased its holdings in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) by 5.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 332,126 shares of the biotechnology company’s stock after selling 18,776 shares during the quarter. Jane Street Group LLC’s holdings in Heron Therapeutics were worth $661,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Clearline Capital LP lifted its position in shares of Heron Therapeutics by 48.9% during the 3rd quarter. Clearline Capital LP now owns 2,226,512 shares of the biotechnology company’s stock worth $4,431,000 after buying an additional 731,246 shares during the last quarter. Congress Park Capital LLC raised its stake in Heron Therapeutics by 25.3% during the 3rd quarter. Congress Park Capital LLC now owns 1,978,078 shares of the biotechnology company’s stock worth $3,936,000 after acquiring an additional 399,577 shares in the last quarter. Marshall Wace LLP lifted its position in Heron Therapeutics by 256.2% in the second quarter. Marshall Wace LLP now owns 1,761,051 shares of the biotechnology company’s stock valued at $6,164,000 after acquiring an additional 1,266,697 shares during the last quarter. AQR Capital Management LLC boosted its stake in Heron Therapeutics by 1,460.9% in the second quarter. AQR Capital Management LLC now owns 607,135 shares of the biotechnology company’s stock valued at $2,125,000 after acquiring an additional 568,238 shares in the last quarter. Finally, GSA Capital Partners LLP grew its holdings in shares of Heron Therapeutics by 18.4% during the third quarter. GSA Capital Partners LLP now owns 512,736 shares of the biotechnology company’s stock worth $1,020,000 after purchasing an additional 79,680 shares during the last quarter. 80.01% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. StockNews.com downgraded Heron Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday. Needham & Company LLC reiterated a “buy” rating and issued a $4.00 price objective on shares of Heron Therapeutics in a research note on Wednesday, December 4th.

Heron Therapeutics Stock Performance

Shares of NASDAQ:HRTX opened at $1.66 on Friday. Heron Therapeutics, Inc. has a one year low of $1.04 and a one year high of $3.93. The stock has a market capitalization of $252.48 million, a price-to-earnings ratio of -9.22 and a beta of 1.60. The company has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $2.07.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $32.81 million for the quarter, compared to analysts’ expectations of $36.40 million. During the same period in the prior year, the company earned ($0.17) earnings per share. As a group, research analysts forecast that Heron Therapeutics, Inc. will post -0.13 EPS for the current fiscal year.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.